• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Qilian International Holding Group Ltd.

    4/9/24 7:27:29 PM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QLI alert in real time by email
    S-8 1 tm249599d2_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on April 9, 2024.

     

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Qilian International Holding Group Limited

    (Exact Name of Registrant as Specified in Its Charter)

     

    Cayman Islands   Not Applicable
    (State or Other Jurisdiction of   (I.R.S. Employer
    Incorporation or Organization)   Identification No.)

     

    No. 152 Hongliang East 1st Street, No. 1703,

    Tianfu New District, Chengdu, 610200

    People’s Republic of China

    Telephone: 86-028-64775180

    (Address, Including Zip Code, of Principal Executive Offices)

     

    Qilian International Holding Group Limited

    2024 Equity Incentive Plan

    (Full Title of the Plan)

     

    Puglisi & Associates

    850 Library Avenue, Suite 204

    Newark, DE 19711

    +1 (302) 738-6680

    (Name, Address and Telephone Number, Including Area Code, of Agent for Service)

     

    Copies To:

     

    Joan Wu, Esq.

    Hunter Taubman Fischer & Li LLC

    950 Third Avenue, 19th Floor

    New York, NY 10022

    (212) 530-2210

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

     

    Large accelerated filer ¨ Accelerated filer ¨
    Non-accelerated filer x Smaller reporting company x
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    This registration statement on Form S-8 (the “Registration Statement”) is being filed by Qilian International Holding Group Limited (the “Registrant”) in accordance with the requirements of Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”), in order to register 5,362,500 ordinary shares, par value $0.00166667 per share (the “Ordinary Shares”), issuable pursuant to the 2024 Equity Incentive Plan (the “Plan”) adopted by the board of directors (the “Board”) of the Registrant.

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN SECTION 10(a) PROSPECTUS

     

    Item 1. Plan Information*

     

    Item 2. Registrant Information and Employee Plan Annual Information*

     

    * Information required by Part I to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act and the Note to Part I of Form S-8. The documents containing information specified in this Part I will be separately provided to the participants covered by the Plan, as specified by Rule 428(b)(1) under the Securities Act.

     

    1

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Certain Documents by Reference.

     

    The following documents previously filed or furnished by the Registrant with the SEC are incorporated herein by reference in this Registration Statement:

     

      (a) The Company’s Annual Report on Form 20-F for its fiscal year ended September 30, 2023, filed with the SEC on February 15, 2024;
         
      (b) the Company’s Current Reports on Form 6-K, as filed with the SEC on March 11, 2024;   the description of the Company’s Ordinary Shares contained in the Company’s registration statements on Form 8-A, filed with the SEC on December 14, 2020, and any amendment or report filed for
         
      (c) the purpose of updating such description (File No. 001-39805);
         
      (d) All other reports filed by the Company pursuant to Section 13(a) or 15(d) of the Exchange Act, since the end of the fiscal year covered by its Annual Report referred to in (a) above (other than information deemed to have been “furnished” rather than “filed” in accordance with the SEC’s rules); and
         
      (e) The description of the Company’s Securities contained in the Company’s Annual Report on Form 20-F for its fiscal year ended September 30, 2023, filed with the SEC on February 15, 2024.

     

    All documents filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the date hereof, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that, unless expressly incorporated into this registration statement, documents or information deemed to have been furnished and not filed in accordance with SEC rules shall not be deemed incorporated by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

     

    II-1 

     

     

    Item 4.Description of Securities.

     

    Not applicable.

     

    Item 5.Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6.Indemnification of Directors and Officers.

     

    Cayman Islands law does not limit the extent to which a company's memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime.

     

    The Registrant’s amended and restated memorandum and articles of association provide that its directors and officers shall be indemnified and secured harmless against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such director or officer, other than by reason of such person's own dishonesty in or about the conduct of the Registrant's business or affairs or in the execution or discharge of his duties, powers, authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such director or officer in defending (whether successfully or otherwise) any civil criminal, administrative or investigative proceedings (whether threatened, pending or completed) concerning the Registrant or its affairs in any court whether in the Cayman Islands or elsewhere. This standard of conduct is generally the same as permitted under the Delaware General Corporation Law for a Delaware corporation.

     

    Pursuant to the indemnification agreements, the form of which was filed as Exhibit 10.3 to the Registrant’s registration statement on Form F-1, as amended (File No. 333-234460), the Registrant has agreed to indemnify its directors and officers against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being such a director or officer.

     

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Registrant pursuant to the foregoing provisions, the Registrant has been informed that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

     

    Item 7.Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8.Exhibits.

     

    The Exhibit Index immediately preceding the exhibits is incorporated herein by reference.

     

    II-2 

     

     

    Item 9.Undertakings.

     

    (a) The undersigned registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of a prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    provided, however, that paragraphs (1)(i) and (1)(ii) do not apply if the information required to be included in the post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this registration statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    II-3 

     

     

    EXHIBIT INDEX

     

    Exhibit    
    Number   Description of Exhibit
    3.1 Amended and Restated Memorandum and Articles of Association (incorporated herein by reference to Exhibit 3.1 to our registration statement on Form F-1 (File No. 333-234460), as amended, initially filed with the SEC on November 4, 2019)
       
    4.1 Description of Securities (incorporated herein by reference to Exhibit 2.2 on Form 20-F filed with the SEC on April 19, 2023)
         
    10.1   2024 Equity Incentive Plan of Qilian International Holding Group Limited
         
    5.1   Opinion of Ogier, regarding the legality of the Ordinary Shares being registered
         
    23.1   Consent of ZH CPA,LLC., an independent registered public accounting firm
         
    23.2   Consent of Friedman LLP., an independent registered public accounting firm
         
    23.3   Consent of Ogier (included in Exhibit 5.1)
         
    24.1   Power of Attorney (included on signature page hereto)
         
    107   Filing Fee Table

     

    II-4 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Form S-8 Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in China on April 9, 2024.

     

      Qilian International Holding Group Limited
       
      By:  /s/ Zhanchang Xin
      Name:  Zhanchang Xin
      Title: Chief Executive Officer and Chairman of the Board of Directors

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints Zhanchang Xin as his or her true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto and other documents in connection therewith) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on April 9, 2024.

     

    Name   Title
         
    /s/ Zhanchang Xin   Chief Executive Officer and Chairman of the Board of Directors
    Zhanchang Xin   (Principal Executive Officer)
         
    /s/ Haiping Shi   Chief Financial Offer
    Haiping Shi   (Principal Financial Officer)
         
    /s/ Song Gao   Independent Director
    Song Gao    
         
    /s/ Ming Jing   Independent Director
    Ming Jing    
         
    /s/ Maofan Tang   Independent Director
    Maofan Tang    
         
    /s/ Dingqian Liu   Director
    Dingqian Liu    
         

     

    II-5 

     

     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

     

    Pursuant to the Securities Act of 1933 as amended, the undersigned, the duly authorized representative in the United States of America, has signed this registration statement thereto in Newark, Delaware, on April 9, 2024.

     

     

    Authorized U.S. Representative  
       
    Puglisi & Associates  
         
    By: /s/ Donald J. Puglisi  
      Name: Donald J. Puglisi  
      Title: Managing Director  

     

    II-6 

     

    Get the next $QLI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QLI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QLI
    SEC Filings

    View All

    SEC Form 6-K filed by Qilian International Holding Group Ltd.

    6-K - Qilian International Holding Group Ltd (0001779578) (Filer)

    6/6/24 4:15:24 PM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Qilian International Holding Group Ltd.

    6-K - Qilian International Holding Group Ltd (0001779578) (Filer)

    6/4/24 9:25:25 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Qilian International Holding Group Ltd.

    EFFECT - Qilian International Holding Group Ltd (0001779578) (Filer)

    5/17/24 12:15:27 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QLI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Qilian International Holding Group Ltd. Announces Trading Ticker Symbol to "BGM"

    CHENGDU, China, Aug. 13, 2024 /PRNewswire/ -- Qilian International Holding Group Ltd. ("Qilian" or the "Company") (NASDAQ:QLI), a China-based pharmaceutical and chemical products manufacturer, announced today that effective on August 11, 2024, its Class A ordinary shares will begin trading on the Nasdaq Capital Market under the ticker symbol "BGM". The new ticker symbol will replace the Company's current ticker symbol "QLI." No action by the Company's shareholders is required with respect to the ticker symbol change. The Company's Class A ordinary shares will continue to be listed on the Nasdaq Capital Market and the CUSIP number remains unchanged. About Qilian International Holding Group L

    8/13/24 8:00:00 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qilian International Holding Group Ltd Regained Compliance with Nasdaq's Minimum Bid Price Rule

    CHENGDU, China, July 12, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ:QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that on July 10, 2024, NASDAQ notified the Company that it has determined that for the 10 consecutive business days, from June 21, 2024 to July 9, 2024, the closing bid price of the Company's Class A ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and NASDAQ has closed this matter. About Qilian International Holding Group Ltd Qilian International Holding Group Ltd, headquartered in Gansu, China, is

    7/12/24 8:30:00 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qilian International Holding Group Limited Announces 1 for 5 Reverse Share Split

    CHENGDU, China, June 18, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ:QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced today that an 1 for 5 reverse split of its authorized share capital, was approved by the Company's board of directors on May 29, 2023 and will become effective on June 21, 2024. In connection with the reverse share split, the Company's shareholders will receive one new Class A ordinary share or Class B ordinary share of the Company for every five Class A ordinary shares or every five Class B ordinary shares they hold, respectively. The Company's Class A ordinary shares are expected to begi

    6/18/24 8:30:00 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QLI
    Financials

    Live finance-specific insights

    View All

    Qilian International Holding Group Ltd Declares Special Cash Dividends to Shareholders

    JIUQUAN, China, Feb. 16, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd ((the ", Company", NASDAQ:QLI), a China-based pharmaceutical and chemical products manufacturer, announced today that the Company has declared a special one-time cash dividend of $0.05 per ordinary share, payable in cash on or about March 6, 2023, to shareholders of record on February 28, 2023. "Despite the impacts of COVID-19 on us in our last fiscal year, the Company maintained decent operating results and healthy cash flow. We expect better financial results as China announced a rollback of its anti-COVID measures." said Mr. Zhanchang Xin, CEO of the Company. About Qilian International Holding Group Ltd Q

    2/16/23 4:30:00 PM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care